WGS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP announces that purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), have until Monday, August 3, 2026 to seek appointment as lead plaintiff of the GeneDx class action lawsuit. Captioned Basma v. GeneDx Holdings Corp. , No. 26-cv-00880 (D. Conn.), the GeneDx class action lawsuit charges GeneDx as well as certain of GeneDx's top executive officers with violations of the Securities Exchange Act of 1934.

GeneDx is a genomics company that provides genetic testing services. On April 16, 2025, GeneDx announced an agreement to acquire Fabric Genomics. Fabric Genomics is a firm focused on AI-driven genomic interpretation. The GeneDx class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose significant problems in Fabric Genomic's viability that would negatively impact GeneDx's overall business and operations.

On May 4, 2026, GeneDx announced its 2026 first quarter results, allegedly revealing a drop in adjusted gross margin from 74% to 69%, reduced projected earnings from $540-$555 million to $475-$490 million, and a $31.3 million impairment loss directly attributable to Fabric Genomics. On this news, the price of GeneDx stock dropped over 49%, according to the complaint.